




REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF FINANCE
BUREAU OF INTERNAL REVENUE



07 December 2022

REVENUE MEMORANDUM CIRCULAR NO. 156-2022


SUBJECT : Publishing the Full Text of the November 23, 2022 Letter from the Food and Drug Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Medicines Under Republic Act (R.A.) No. 11534 Known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act

TO : All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the November 23, 2022 letter (Annex "A") from Dr. Samuel A. Zacate, Director General of the FDA, for inclusion of certain medicines prescribed for hypertension, diabetes, high cholesterol, tuberculosis, mental illness, and cancer to the published List of VAT-Exempt Medicines Under R.A. No. 11534 or the CREATE Act.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.

All concerned are hereby enjoined to be guided accordingly and give this Circular as wide a publicity as possible.


ROMEO D. LUMAGUI, JR.
Commissioner of Internal Revenue

000836